This is the first study to use an established simulation model to quantify the lifetime risk of contralateral breast cancer among the US female population with primary non-metastatic ER+/HER2- cancer and to provide estimates within 56 sub-groups based on primary endocrine therapy type, duration, and age at the diagnosis of the first primary cancer. This evidence concerns the gene ERBB2 and breast carcinoma.